Congratulations! Healrna Honored as a 2022 Gusu Innovation and Entrepreneurship Leading Talent Enterprise

On September 21, 2022, the Suzhou Municipal Bureau of Finance, in collaboration with the Suzhou Municipal Science and Technology Bureau, released the "Notice on the Twentieth Batch of Science and Technology Development Plan (Talent Special) Projects and Science and Technology Funds for 2022 in Suzhou." The project "Development and Industrialization of a New Generation of Independently Developed mRNA Drug Delivery Platform," led by Dr. Zhong Tianyi, founder and CEO of Healrna, was successfully selected.

#About Healrna #

Healrna is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.